Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc.

ATRA

Insider Sentiment (TTM):

Last Purchase:2026-05-07Last Sale:2026-05-18Shares Purchased (TTM):562,407Shares Sold (TTM):416,241

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:2,433,234Shares Outstanding:14,081,000Institutional Ownership Pct.:17.28%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	8	8	6	17	14	25	46	31	35	26	65	46
Short Term Investments	-	0	8	5	0	17	21	4	11	26	38	108
Restricted Cash Current	-	0	0	0	0	0	0	0	0	0	0	0
Accounts Receivable Net Current	0	1	2	0	9	1	1	2	36	34	0	1
Inventory Net	-	0	0	0	0	11	14	19	16	10	7	8
Other Assets Current	4	2	3	2	4	10	9	6	8	6	9	10
Assets Current	12	12	18	25	27	65	92	62	106	102	119	172
Property Plant And Equipment Net	0	0	0	0	0	1	2	2	3	4	5	5
Operating Lease Right Of Use Asset	7	7	11	11	32	40	46	49	52	55	59	62
Other Assets Noncurrent	1	1	1	1	3	3	3	4	4	5	6	7
Assets	20	20	30	37	62	109	143	117	165	166	189	246
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	0	0	2	1	4	2	5	3	4	7	4
Employee Related Liabilities Current	1	1	2	3	5	7	8	7	6	12	14	13
Deferred Income Current	1	1	1	2	16	95	116	108	123	78	12	12
Other Liabilities Current	3	3	5	8	24	20	24	26	33	32	23	25
Liabilities Current	6	15	18	15	48	135	156	148	181	142	79	75
Contract With Customer Liability Noncurrent	-	-	-	0	0	0	0	1	1	38	74	76
Operating Lease Liability Noncurrent	9	9	15	15	27	30	35	39	42	46	49	52
Other Liabilities Noncurrent	2	2	2	2	3	3	4	4	4	5	5	5
Liabilities	57	59	67	72	117	206	233	228	264	265	240	239
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,989	1,983	1,982	1,979	1,961	1,957	1,951	1,909	1,903	1,870	1,858	1,847
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	0	-0	-0	-0	-1	-1
Retained Earnings Accumulated Deficit	-2,026	-2,022	-2,018	-2,014	-2,017	-2,055	-2,042	-2,020	-2,001	-1,969	-1,909	-1,839
Stockholders Equity	-37	-39	-37	-35	-55	-97	-91	-111	-98	-99	-51	7
Liabilities And Stockholders Equity	20	20	30	37	62	109	143	117	165	166	189	246
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	9	7	7	7	6	6	6	5	120	4	102	101
Shares Outstanding	9	7	7	7	6	6	6	5	120	4	102	101

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.12%	18.76%	-	-	-	-	-	-	-	-	-	-
2025	21.29%	11.24%	51.77%	25.10%	39.63%	43.90%	14.92%	42.50%	-58.30%	-20.78%	42.08%	68.99%
2024	2.75%	-37.73%	-25.49%	21.88%	-1.03%	24.97%	11.65%	40.10%	-23.91%	-5.36%	6.09%	3.48%
2023	-	-	-	-31.72%	-34.80%	-44.93%	-48.25%	-56.98%	-49.60%	-4.76%	-12.10%	-26.37%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.16	0.82	1.02	1.70	0.57	0.48	0.59	0.42	0.59	0.72	1.50	2.31
Quick Ratio	2.16	0.82	1.02	1.70	0.57	0.40	0.50	0.29	0.50	0.65	1.42	2.21
Working Capital	6.53M	-2.71M	375.00K	10.21M	-20.71M	-69.68M	-64.12M	-85.86M	-74.26M	-40.36M	39.61M	97.77M
Leverage & Debt
Debt to Equity	-1.54	-1.53	-1.82	-2.05	-2.13	-2.12	-2.58	-2.06	-2.68	-2.67	-4.71	32.06
Interest Coverage TTM	-1.75	9.46	6.70	1.92	-2.99	-18.08	-27.48	-35.91	-45.52	-52.22	-69.00	-103.79
Debt Ratio	2.87	2.90	2.21	1.95	1.89	1.89	1.63	1.95	1.59	1.60	1.27	0.97
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.39	0.95	0.90	0.94	0.61	0.34	0.15	0.03	0.02	0.02
Days Sales Outstanding TTM	-	730.80	17.78	-	80.14	50.37	2.72	8.57	190.53	1,582.30	16.55	30.42
Receivables Turnover TTM	-	0.50	20.53	-	4.55	7.25	134.10	42.60	1.92	0.23	22.05	12.00
Per Share Metrics
Diluted EPS TTM	-0.67	2.57	1.73	0.47	-1.44	-11.41	-17.84	-29.47	-41.46	-65.19	-68.20	-72.44
Free Cash Flow Per Share TTM	-1.84	-4.06	-5.15	-5.25	-6.26	-9.21	-12.70	-23.20	-32.92	-45.85	-47.15	-50.96
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	819.56%	655.20%	111.74%	105.71%	104.40%	103.58%	104.75%	107.99%	114.70%	161.65%	193.04%	143.04%
Operating Profit Margin TTM	-1,259.28%	5,250.66%	78.66%	10.96%	-13.15%	-64.71%	-130.62%	-287.00%	-669.19%	-3,219.48%	-6,419.70%	-4,467.33%
Net Profit Margin TTM	-1,889.62%	4,785.94%	70.20%	7.90%	-15.36%	-66.23%	-132.58%	-290.20%	-671.70%	-3,220.88%	-6,390.31%	-4,437.45%
Growth Metrics
Net Revenue Growth (1Y)	-99.51%	-99.47%	-66.81%	17.53%	193.39%	1,404.02%	2,111.34%	809.03%	-39.63%	-86.51%	-92.83%	-88.35%
Net Income Growth (1Y)	-39.47%	-138.28%	-117.57%	-103.20%	-93.29%	-69.07%	-54.12%	-40.55%	8.44%	20.95%	17.47%	22.97%
EPS Growth (1Y)	-53.73%	-122.85%	-109.67%	-101.61%	-96.49%	-82.50%	-73.85%	-59.32%	-19.80%	16.48%	13.08%	18.88%
Valuation Metrics
P/E TTM	-7.04	6.94	8.31	16.25	-4.09	-1.17	-0.46	-0.29	-0.42	-0.20	-0.54	-0.56
P/B TTM	-1.79	-5.89	-5.31	-2.69	-1.16	-1.02	-0.67	-0.47	-0.99	-0.55	-3.10	22.70
P/S TTM	132.94	332.24	5.83	1.28	0.63	0.77	0.60	0.84	2.81	6.34	34.67	24.66
Market Cap	66.60M	226.92M	194.37M	94.16M	63.94M	99.67M	60.70M	52.22M	97.56M	54.33M	157.47M	169.21M
Enterprise Value	58.24M	218.44M	188.63M	77.26M	49.95M	74.49M	14.10M	20.76M	62.33M	28.34M	92.54M	123.17M
Calculated Values
Free Cash Flow TTM	-25.88M	-50.94M	-69.80M	-64.01M	-67.36M	-68.96M	-94.85M	-142.49M	-185.11M	-194.20M	-200.67M	-214.23M
Net Debt	-8.36M	-8.48M	-5.74M	-16.90M	-13.99M	-25.18M	-46.60M	-31.46M	-35.23M	-25.99M	-64.94M	-46.04M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-18Sale

Owner: Grant-Huerta, Yanina

Title: Chief Accounting Officer

Shares: 2,414

Price/Share: $9.13

Value: $22,039.82

Shares Owned: 49,636

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Nguyen, Anhco

Title: President and CEO

Shares: 5,241

Price/Share: $9.13

Value: $47,850.33

Shares Owned: 137,837

Relationship: Director,Officer

Ownership: Direct

2026-05-07Sale

Owner: Panacea, Innovation Ltd, …

Title: -

Shares: 313,446

Price/Share: $10.10

Value: $3,165,804.60

Shares Owned: 1,011,000

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-05-07Purchase

Owner: Ecor1, Capital, Llc

Title: -

Shares: 507,407

Price/Share: $9.35

Value: $4,744,255.45

Shares Owned: 1,552,000

Relationship: TenPercentOwner

Ownership: Indirect

2026-03-02Sale

Owner: Nguyen, Anhco

Title: President and CEO

Shares: 2,996

Price/Share: $5.08

Value: $15,219.68

Shares Owned: 61,978

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-18	Grant-Huerta, Yanina	Officer	Chief Accounting Officer	Direct	Sale	2,414	9.13	$22,039.82	49,636	4
2026-05-18	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	5,241	9.13	$47,850.33	137,837	4
2026-05-07	Panacea, Innovation Ltd, …	Director,TenPercentOwner	-	Indirect	Sale	313,446	10.10	$3,165,804.60	1,011,000	4
2026-05-07	Ecor1, Capital, Llc	TenPercentOwner	-	Indirect	Purchase	507,407	9.35	$4,744,255.45	1,552,000	4
2026-03-02	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	2,996	5.08	$15,219.68	61,978	4
2026-03-02	Grant-Huerta, Yanina	Officer	Chief Accounting Officer	Direct	Sale	2,104	5.08	$10,688.32	31,750	4
2026-01-12	Huang, James, Panacea Inn…	TenPercentOwner	-	Indirect	Sale	80,554	6.07	$488,962.78	1,324,446	4
2025-11-17	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	2,915	13.19	$38,448.85	64,974	4
2025-11-17	Grant-Huerta, Yanina	Officer	Chief Accounting Officer	Direct	Sale	1,804	13.19	$23,794.76	33,454	4
2025-08-18	Grant-Huerta, Yanina	Officer	Chief Accounting Officer	Direct	Sale	1,809	11.61	$21,002.49	35,258	4
2025-08-18	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	2,958	11.62	$34,371.96	67,889	4
2025-08-15	Panacea, Innovation Ltd, …	Director,TenPercentOwner	-	Indirect	Purchase	55,000	12.19	$670,450.00	1,405,000	4
2025-07-17	Huang, James, Panacea Inn…	TenPercentOwner	-	Indirect	Purchase	19,335	9.64	$186,389.40	1,350,000	4
2025-05-16	Grant-Huerta, Yanina	Officer	Chief Accounting Officer	Direct	Sale	2,218	6.76	$14,993.68	37,067	4
2025-05-16	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	3,276	6.76	$22,145.76	70,847	4
2025-03-03	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	3,331	7.00	$23,317.00	74,123	4
2025-03-03	Hyllengren, Eric J	Officer	EVP, CFO and COO	Direct	Sale	1,211	7.00	$8,477.00	56,231	4
2025-03-03	Henrich, Jill	Officer	EVP, Chief Regulatory Officer	Direct	Sale	1,059	7.00	$7,413.00	18,679	4
2024-11-18	Nguyen, Anhco	Director,Officer	President and CEO	Direct	Sale	1,664	11.20	$18,636.80	77,454	4
2024-11-18	Henrich, Jill	Officer	EVP, Chief Regulatory Officer	Direct	Sale	1,000	11.20	$11,200.00	19,378	4
2024-11-18	Hyllengren, Eric J	Officer	EVP, CFO and COO	Direct	Sale	1,364	11.20	$15,276.80	23,392	4
2024-08-16	Henrich, Jill	Officer	EVP, Global Head RA & Quality	Direct	Sale	963	6.63	$6,384.69	20,378	4
2024-08-16	Hyllengren, Eric J	Officer	EVP, CFO	Direct	Sale	1,070	6.63	$7,094.10	24,756	4
2024-08-16	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	3,038	6.63	$20,141.94	70,127	4
2024-08-16	Nguyen, Anhco	Officer	EVP, Chief Sci. & Tech Officer	Direct	Sale	1,821	6.63	$12,073.23	34,118	4
2024-08-16	Murugan, Amar	Officer	EVP, Chief Legal Officer	Direct	Sale	1,158	6.63	$7,677.54	26,827	4
2024-05-16	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	81,506	0.62	$50,533.72	1,829,146	4
2024-05-16	Nguyen, Anhco	Officer	EVP, Chief Sci. & Tech Officer	Direct	Sale	42,899	0.62	$26,597.38	898,498	4
2024-05-16	Henrich, Jill	Officer	EVP, Global Head RA & Quality	Direct	Sale	25,750	0.62	$15,965.00	529,251	4
2024-05-16	Murugan, Amar	Officer	EVP, Chief Legal Officer	Direct	Sale	32,401	0.62	$20,088.62	695,120	4
2024-05-16	Hyllengren, Eric J	Officer	EVP, CFO	Direct	Sale	28,648	0.62	$17,761.76	645,671	4
2024-03-04	Murugan, Amar	Officer	EVP, Chief Legal Officer	Direct	Sale	10,044	0.72	$7,231.68	727,521	4
2024-03-04	Henrich, Jill	Officer	EVP, Global Head RA & Quality	Direct	Sale	3,879	0.72	$2,792.88	555,001	4
2024-03-04	Hyllengren, Eric J	Officer	EVP, CFO	Direct	Sale	6,679	0.72	$4,808.88	674,319	4
2024-03-04	Nguyen, Anhco	Officer	EVP, Chief Sci. & Tech Officer	Direct	Sale	10,746	0.72	$7,737.12	941,397	4
2024-03-04	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	24,844	0.72	$17,887.68	1,910,652	4
2023-11-16	Murugan, Amar	Officer	EVP, Chief Legal Officer	Direct	Sale	8,307	0.39	$3,239.73	257,084	4
2023-11-16	Joshi, Manher	Officer	EVP, Chief Medical Officer	Direct	Sale	12,287	0.39	$4,791.93	171,284	4
2023-11-16	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	20,409	0.39	$7,959.51	655,496	4
2023-11-16	Henrich, Jill	Officer	EVP, Global Head RA & Quality	Direct	Sale	3,267	0.39	$1,274.13	104,424	4
2023-11-16	Nguyen, Anhco	Officer	EVP, Chief Sci. & Tech Officer	Direct	Sale	8,856	0.39	$3,453.84	277,143	4
2023-11-16	Hyllengren, Eric J	Officer	SVP, CFO	Direct	Sale	11,958	0.39	$4,663.62	205,998	4
2023-11-14	Gallagher, Carol Giltner	Director	-	Direct	Purchase	90,980	0.31	$28,203.80	459,418	4
2023-11-10	Heiden, William K	Director	-	Direct	Purchase	100,000	0.25	$25,000.00	209,000	4
2023-11-10	Dobmeier, Eric	Director	-	Direct	Purchase	446,825	0.23	$102,769.75	563,325	4
2023-08-16	Nguyen, Anhco	Officer	EVP, Chief Sci. & Tech Officer	Direct	Sale	15,126	1.65	$24,957.90	285,999	4
2023-08-16	Joshi, Manher	Officer	EVP, Chief Medical Officer	Direct	Sale	6,975	1.65	$11,508.75	183,571	4
2023-08-16	Murugan, Amar	Officer	EVP, Chief Legal Officer	Direct	Sale	8,672	1.65	$14,308.80	265,391	4
2023-08-16	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	30,766	1.65	$50,763.90	675,905	4
2023-08-16	Henrich, Jill	Officer	EVP, Global Head RA & Quality	Direct	Sale	3,346	1.65	$5,520.90	107,691	4
2023-08-16	Hyllengren, Eric J	Officer	SVP, CFO	Direct	Sale	8,186	1.65	$13,506.90	217,956	4
2023-06-27	Touchon, Pascal	Director,Officer	President and CEO	Direct	Sale	14,291	1.66	$23,723.06	706,671	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

17.28%

Inst. Shares: 2,433,234

Shares Outstanding: 14,081,000

2025-12-31

15.73%

Inst. Shares: 1,972,844

Shares Outstanding: 12,544,000

2025-09-30

13.15%

Inst. Shares: 1,783,497

Shares Outstanding: 13,564,000

2025-06-30

14.10%

Inst. Shares: 1,719,289

Shares Outstanding: 12,197,000

2025-03-31

18.13%

Inst. Shares: 1,951,360

Shares Outstanding: 10,764,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	2,433,234	14,081,000	17.28%
2025-12-31	1,972,844	12,544,000	15.73%
2025-09-30	1,783,497	13,564,000	13.15%
2025-06-30	1,719,289	12,197,000	14.10%
2025-03-31	1,951,360	10,764,000	18.13%
2024-12-31	2,243,483	7,488,000	29.96%
2024-09-30	2,285,211	7,466,000	30.61%
2024-06-30	2,534,292	6,143,000	41.25%
2024-03-31	2,981,323	5,623,000	53.02%
2023-12-31	2,435,588	4,236,000	57.50%
2023-09-30	3,020,351	4,256,000	70.97%
2023-06-30	3,038,920	4,204,000	72.29%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Atara Biotherapeutics, Inc. (ATRA) — SEC Financial Statements & Analysis

Atara Biotherapeutics, Inc. (ATRA) is a biological products, (no diagnostic substances) company, incorporated in DE. Atara Biotherapeutics, Inc. trades on Nasdaq as: ATRA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Atara Biotherapeutics, Inc. reported a -99.51% year-over-year revenue growth, a Gross Profit Margin of 819.56% (TTM), a Debt-to-Equity ratio of -1.54x, a Price-to-Sales (P/S) ratio of 132.94x (TTM), a Price-to-Book (P/B) ratio of -1.79 (TTM), at a market cap of $66.60M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -99.51%
Gross Profit Margin TTM: 819.56%
Debt To Equity: -1.54x
P/S TTM: 132.94x
P/B TTM: -1.79
Market Cap: $66.60M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Atara Biotherapeutics, Inc. in?

Atara Biotherapeutics, Inc. (ATRA) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ATRA's market cap?

Atara Biotherapeutics, Inc. (ATRA) has a market capitalization of $66.60M as of 2026-03-31.

What exchange does ATRA trade on?

Atara Biotherapeutics, Inc. (ATRA) trades on the Nasdaq.

Where is Atara Biotherapeutics, Inc. incorporated?

Atara Biotherapeutics, Inc. is incorporated in DE.

Atara Biotherapeutics, Inc. (ATRA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.